• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PIPELINE
    ▼
    • Overview
  • FOR PATIENTS
    ▼
    • Clinical Trials
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PIPELINE
    • Overview
  • FOR PATIENTS
    • Clinical Trials
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Conferences

Conferences

Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity

June 5, 2025 | 62nd ERA Congress
Kirk J. Rowley, et al.

Differential Impacts of APRIL and APRIL/BAFF Inhibition on Immune Populations: Implications for IgA Nephropathy Treatment and Protective Immunity

Kirk J. Rowley, Vinay Singh, Anna Roberts, Katherine A. Heang, Prashanna B. Venkatasubramanian, Jacob V. Konaklonda, Daved Fared, Michelle Lu, Brett Hurst, Wayne W. Hancock, Gregory J. Babcock, Luke N. Robinson

>SEE POSTER

Preclinical Development of VIS171 – A Novel Modified IL-2 Safely and Selectively Upregulates Regulatory T Cells to Treat Autoimmune Diseases

September 6, 2024 | Promise of Interleukin-2 Therapy Conference
John J. O’Neil, et al.

Preclinical Development of VIS171 – A Novel Modified IL-2 Safely and Selectively Upregulates Regulatory T Cells to Treat Autoimmune Diseases

John J. O’Neil, Greg J. Babcock, Zach Shiver, David Oldach, Susan Sloan

Modified-IL-2 (VIS171) to Preferentially Induce Regulatory T Cells in Nonhuman Primates

September 6, 2024 | Promise of Interleukin-2 Therapy Conference
John J. O’Neil, et al.

Modified-IL-2 (VIS171) to Preferentially Induce Regulatory T Cells in Nonhuman Primates

John J. O’Neil, Davide Schiliró, Joe M. Ladowski, Janghoon Yoon, Angela Park, Rafaela Belloni, Asher D. Schachter, David Oldach, Gregory J. Babcock, Jean Kwun, Stuart Knechtle

Tissue-resident ST2+ regulatory T cells promote cardiac transplant tolerance induced by a mutein IL-2

June 2, 2024 | American Transplant Congress
Yoshikazu Ganchiku, et al.

Tissue-resident ST2+ regulatory T cells promote cardiac transplant tolerance induced by a mutein IL-2

Yoshikazu Ganchiku, Rodrigo Gassen, Orhan Efe, Zach Shriver, Gregory J. Babcock, Thiago J. Borges, Leonardo V. Riella

Sibeprenlimab in patients with IgA nephropathy: a Phase 2 trial

November 2, 2023 | American Society of Nephrology (ASN) Kidney Week
Jonathan Barratt, et.al.

Sibeprenlimab in patients with IgA nephropathy: a Phase 2 trial

Jonathan Barratt, Mohit Mathur, Bobby Chacko, Tak Mao Chan, Laura Kooienga, Kook-Hwan Oh, Manisha Sahay, Yusuke Suzuki, Muh Geot Wong, Jill Yarbrough, Jing Xia, Brian J G Pereira

>SEE POSTER

COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): A Preliminary Analysis

June 15, 2023 | 60th ERA Congress
McCafferty, et. al.

COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): A Preliminary Analysis

Kieran McCafferty, Marcella Pasetti, Asher Schachter, Mohit Mathur, Diane Ma, Jill Yarbrough, Mallory Shriver, Kristin Follman, Frank Engler, Yusuke Suzuki, David Oldach

Strategies For Development Of Interleukin-2 Therapy In Transplant Recipients: What Works And What Doesn’t

June 3, 2023 | American Transplant Congress
Wang, et. al.

Strategies For Development Of Interleukin-2 Therapy In Transplant Recipients: What Works And What Doesn’t

Liqing Wang, Gregory J Babcock, Wayne W Hancock

>SEE POSTER

A Novel IL-2 Mutein Induces Regulatory T Cell-Rich Microenvironment and Leads to Alloantigen-Specific Graft Acceptance

June 3, 2023 | American Transplant Congress
Ganchiku, et. al.

A Novel IL-2 Mutein Induces Regulatory T Cell-Rich Microenvironment and Leads to Alloantigen-Specific Graft Acceptance

Yoshikazu Ganchiku, Thiago J Borges, Rodrigo B Gassen, Orhan Efe, Zach Shriver, Gregory J Babcock, Leonardo V Riella

>SEE POSTER

Selective Regulatory T-Cell Expansion by A Novel IL-2 Mutein in Murine Transplant and Humanized NSG Models

June 3, 2023 | American Transplant Congress 2023
Efe, et. al.

Selective Regulatory T-Cell Expansion by A Novel IL-2 Mutein in Murine Transplant and Humanized NSG Models

Orhan Efe, Thiago J Borges, Rodrigo B Gassen, Leela Morena, Yoshikazu Ganchiku, Ayman Al Jurdi, Isadora T Lape, Zach Shriver, Gregory J Babcock, Joren C Madsen, Leonardo V Riella

VIS954 is a Potent Anti-C5aR1 Antibody for the Treatment of ANCA-Associated Vasculitis

May 26, 2023 | 15th International Conference on Complement Therapeutics
Lauren Olinski, et al.

VIS954 is a Potent Anti-C5aR1 Antibody for the Treatment of ANCA-Associated Vasculitis

Lauren Olinski, Danielle Wisheart, Daisuke Oka, Lisa Perreault, Boopathy Ramakrishnan, A. Richard Kitching, Gregory Babcock, Zachary Shriver, Karthik Viswanathan

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

© 2026 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design

We use cookies on our website to see how you interact with it. By accepting, you agree to our use of such cookies. Privacy PolicyOk